Taysha Gene Therapies (TSHA) Net Income towards Common Stockholders (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$42.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 96.99% year-over-year to -$42.4 million; the trailing twelve-month figure through Mar 2026 stood at -$129.9 million (down 49.69% YoY), and the FY2025 full-year result was -$109.0 million, down 22.06% from the prior year.
• Net Income towards Common Stockholders declined to -$42.4 million in Q1 2026, from -$27.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $47.7 million in Q4 2023 to a low of -$117.1 million in Q3 2023.
• A 5-year average of -$30.5 million and a median of -$26.5 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Peak annual rise in Net Income towards Common Stockholders reached 186.68% in 2023, while the deepest fall reached 341.39% in 2023.
• Tracing TSHA's Net Income towards Common Stockholders over 5 years: stood at -$55.1 million in 2022, then jumped by 186.68% to $47.7 million in 2023, then sank by 139.35% to -$18.8 million in 2024, then tumbled by 48.26% to -$27.9 million in 2025, then tumbled by 52.27% to -$42.4 million in 2026.
• Business Quant data shows TSHA's Net Income towards Common Stockholders at -$42.4 million in Q1 2026, -$27.9 million in Q4 2025, and -$32.7 million in Q3 2025.